ATM and cancer: Due to the inhibitory effect of Celastrol in the ATR DDR pathway, it will be interesting to test in future studies whether cancer cells with deficiency in ATM or BRCA1/2 are more vulnerable to Celastrol, and whether Celastrol in combination with other small molecules such as PARP1 inhibitors can sensitize cancer cells synergistically.